This study is the inaugural demonstration that vericiguat inhibits TGF-β1/Smad signaling through the PKG pathway, thereby reducing myocardial fibrosis and atrial fibrillation recurrence. The gene discussed is PRKG1; the disease is atrial fibrillation.